for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dr.Reddy's Laboratories Ltd

REDY.NS

現在値

4,881.50INR

変化

31.25(+0.64%)

出来高

530,915

本日のレンジ

4,842.60

 - 

4,890.00

52週レンジ

2,495.05

 - 

5,512.65

∙ 約20分前の相場を表示しています。

適時開示

Dr.Reddy's Says Co, RDIF Commence Clinical Trials For Sputnik V Vaccine In India.

Dec 1 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::DR.REDDY'S LABORATORIES LTD SAYS DR. REDDY''S AND RDIF COMMENCE CLINICAL TRIALS FOR SPUTNIK V VACCINE IN INDIA..DR.REDDY'S LABORATORIES - COMMENCED ADAPTIVE PHASE 2/3 CLINICAL TRIALS FOR SPUTNIK V VACCINE IN INDIA AFTER GETTING CLEARANCE FROM DRUGS REGULATOR.DR.REDDY'S - TRIAL WILL INCLUDE SAFETY AND IMMUNOGENICITY STUDY.

Dr.Reddy's Commences Investigation Into Anonymous Complaint About Providing Improper Benefits

Nov 19 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::HAS COMMENCED A DETAILED INVESTIGATION INTO AN ANONYMOUS COMPLAINT.COMPLAINT ALLEGES HEALTHCARE PROFESSIONALS IN UKRAINE, POTENTIAL OTHER COUNTRIES PROVIDED WITH IMPROPER BENEFITS IN VIOLATION OF U.S. LAWS.INVESTIGATION IS BEING CARRIED OUT BY A INDEPENDENT U.S. LAW FIRM.

Appili Therapeutics Signed A Collaboration, Development And Supply Agreement With Dr. Reddy's Laboratories And Global Response Aid

Oct 30 (Reuters) - Appili Therapeutics Inc <APLI.TO>::APPILI THERAPEUTICS INC - SIGNED A COLLABORATION, DEVELOPMENT AND SUPPLY AGREEMENT WITH DR. REDDY'S LABORATORIES AND GLOBAL RESPONSE AID.APPILI - AGREEMENTS TO ACCELERATE WORLDWIDE DEVELOPMENT, COMMERCIALIZATION OF AVIGAN TABLETS FOR POTENTIAL TREATMENT AND PREVENTION OF COVID-19.APPILI THERAPEUTICS INC - DR. REDDY'S AND GRA WILL CONTINUE TO BE RESPONSIBLE FOR RESEARCH AND DEVELOPMENT, COMMERCIALIZATION, OF AVIGAN.APPILI - WILL BE RESPONSIBLE FOR US & CANADIAN CLINICAL TRIALS CONDUCTED & WILL RECEIVE PROFIT SHARE ON ALL US AND CANADIAN SALES FOR A SPECIFIED TERM.

Dr.Reddy's Labs Names Parag Agarwal CFO

Oct 28 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER.PARAG AGARWAL NAMED CFO.SAUMEN CHAKRABORTY TO RESIGN AS CFO DEC 1.

India's Dr.Reddy's Laboratories Sept-Quarter Consol Net Profit Falls

Oct 28 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::SEPT-QUARTER CONSOL NET PROFIT 7.72 BILLION RUPEES VERSUS PROFIT 11.07 BILLION RUPEES YEAR AGO.SEPT-QUARTER CONSOL NET SALES 47.77 BILLION RUPEES VERSUS 39.98 BILLION RUPEES YEAR AGO.CONSENSUS FORECAST FOR SEPT-QUARTER CONSOL PROFIT WAS 6.34 BILLION RUPEES -- REFINITIV DATA.DR.REDDY'S SAYS RECENT CYBERATTACK WAS RANSOMWARE ATTACK, STILL INVESTIGATING.DR.REDDY'S LABORATORIES LTD - APPROVED TO LIST CO'S AMERICAN DEPOSITORY RECEIPTS ON NSE IFSC LTD.DR.REDDY'S SAYS CYBERATTACK PROBE HAS NOT ASCERTAINED IF ANY DATA BREACH PERTAIN TO PERSONAL INFO.DR.REDDY'S LABORATORIES SAYS ALL CRITICAL OPERATIONS ARE BEING ENABLED IN A CONTROLLED MANNER.

Life Insurance Corp Of India Cuts Stake In Dr.Reddy's From 3.626% To 1.594%

Oct 23 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::LIFE INSURANCE CORP OF INDIA CUTS STAKE IN CO FROM 3.626% TO 1.594%.

Dr.Reddy's Re-Launches Over-The-Counter Famotidine Tablets USP, 10 Mg And 20 Mg

Oct 20 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::ANNOUNCES RE-LAUNCH OF OVER-THE-COUNTER FAMOTIDINE TABLETS USP, 10 MG AND 20 MG.

Dr.Reddy's Settles U.S. Revlimid Capsules Patent Litigation With Celgene

Sept 17 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::ANNOUNCES SETTLEMENT OF U.S. REVLIMID (LENALIDOMIDE) CAPSULES PATENT LITIGATION WITH CELGENE.CELGENE TO PROVIDE CO WITH LICENSE TO SELL VOLUME-LIMITED AMOUNTS OF GENERIC LENALIDOMIDE CAPSULES IN U.S..AGREED-UPON SALES VOLUME PERCENTAGES CONFIDENTIAL.ALSO LICENSED TO SELL GENERIC LENALIDOMIDE IN U.S. WITHOUT VOLUME LIMIT.LICENSE TO SELL VOLUME-LIMITED AMOUNTS OF GENERIC LENALIDOMIDE CAPSULES IN U.S. BEGINS ON CONFIDENTIAL DATE AFTER MARCH 2022.

Dr.Reddy's Labs' Generic Version Of Remdesivir Priced At 5,400 Rupees/100 Mg Vial

Sept 9 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::DR.REDDY'S LABORATORIES' GENERIC VERSION OF REMDESIVIR, REDYX, PRICED AT 5,400 RUPEES PER 100 MG VIAL - STATEMENT.

Dr.Reddy's Laboratories Says Informed By FDA That Warning Letter For 3 Sites Have Been Closed

Aug 28 (Reuters) - Dr.Reddy's Laboratories Ltd <REDY.NS>::DR.REDDY'S LABORATORIES - INFORMED BY FDA THAT WARNING LETTER CLOSED FOR 3 SITES.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up